A statistical framework for assessing pharmacological response and biomarkers using uncertainty estimates

  1. Dennis Wang  Is a corresponding author
  2. James Hensman
  3. Ginte Kutkaite
  4. Tzen S Toh
  5. Ana Claudia Paulo Galhoz
  6. Jonathan R Dry
  7. Julio Saez-Rodriguez
  8. Mathew J Garnett
  9. Michael P Menden  Is a corresponding author
  10. Frank Dondelinger  Is a corresponding author
  1. University of Sheffield, United Kingdom
  2. PROWLER.io, United Kingdom
  3. Helmholtz Zentrum Muenchen, Germany
  4. AstraZeneca, United States
  5. Heidelberg University, Germany
  6. Wellcome Sanger Institute, United Kingdom
  7. Helmholtz Zentrum München, Germany
  8. Lancaster University, United Kingdom

Abstract

High-throughput testing of drugs across molecular-characterised cell lines can identify candidate treatments and discover biomarkers. However, the cells' response to a drug is typically quantified by a summary statistic from a best-fit dose-response curve, whilst neglecting the uncertainty of the curve fit and the potential variability in the raw readouts. Here, we model the experimental variance using Gaussian Processes, and subsequently, leverage uncertainty estimates to identify associated biomarkers with a new Bayesian framework. Applied to in vitro screening data on 265 compounds across 1,074 cancer cell lines, our models identified 24 clinically established drug response biomarkers, and provided evidence for 6 novel biomarkers by accounting for association with low uncertainty. We validated our uncertainty estimates with an additional drug screen of 26 drugs, 10 cell lines with 8 to 9 replicates. Our method is applicable to any dose-response data without replicates, and improves biomarker discovery for precision medicine.

Data availability

All data is available through the GDSC downloads portal (ftp://ftp.sanger.ac.uk/pub4/cancerrxgene/releases)Raw dose response data have been deposited in GDSC under v17a_public_raw_data.csvSigmoid fitted dose-response curves have been deposited in GDSC under v17_fitted_dose_response.csvCell line genomics data have been deposited in GDSC under GDSCtools_mobems.zipCell line identity details have been deposited in GDSC under Cell_Lines_Details.xlsxDrug compound details have been been deposited in GDSC under screened_compunds_rel_8.2.csv

Article and author information

Author details

  1. Dennis Wang

    Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, United Kingdom
    For correspondence
    dennis.wang@sheffield.ac.uk
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0068-1005
  2. James Hensman

    PROWLER.io, Cambridge, United Kingdom
    Competing interests
    James Hensman, James Hensman is an employee of Amazon.com. The author has no competing financial interests to declare..
  3. Ginte Kutkaite

    Computational Biology, Helmholtz Zentrum Muenchen, Munich, Germany
    Competing interests
    No competing interests declared.
  4. Tzen S Toh

    The Medical School, University of Sheffield, Sheffield, United Kingdom
    Competing interests
    No competing interests declared.
  5. Ana Claudia Paulo Galhoz

    Computational Biology, Helmholtz Zentrum Muenchen, Munich, Germany
    Competing interests
    No competing interests declared.
  6. Jonathan R Dry

    AstraZeneca, Boston, United States
    Competing interests
    Jonathan R Dry, Jonathan Dry is affiliated with AstraZeneca. The author has no competing financial interests to declare..
  7. Julio Saez-Rodriguez

    Heidelberg University, Heidelberg, Germany
    Competing interests
    No competing interests declared.
  8. Mathew J Garnett

    Translational Cancer Genomics, Wellcome Sanger Institute, Hinxton, United Kingdom
    Competing interests
    No competing interests declared.
  9. Michael P Menden

    Institute of Computational Biology, Helmholtz Zentrum München, Neuherberg, Germany
    For correspondence
    michael.menden@helmholtz-muenchen.de
    Competing interests
    No competing interests declared.
  10. Frank Dondelinger

    Lancaster University, Lancaster, United Kingdom
    For correspondence
    fdondelinger.work@gmail.com
    Competing interests
    Frank Dondelinger, Frank Dondelinger is an employee of Roche. The author has no competing financial interests to declare..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1816-6300

Funding

NIHR Sheffield Biomedical Research Centre (BRC - IS-BRC-1215-20017)

  • Dennis Wang
  • Tzen S Toh

Rosetrees Trust (A2501)

  • Dennis Wang
  • Tzen S Toh

Academy of Medical Sciences (SBF004/1052)

  • Dennis Wang

Wellcome Trust (206194)

  • Mathew J Garnett

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Joseph Lehár, Boston University, United States

Version history

  1. Received: June 24, 2020
  2. Accepted: December 4, 2020
  3. Accepted Manuscript published: December 4, 2020 (version 1)
  4. Accepted Manuscript updated: December 7, 2020 (version 2)
  5. Version of Record published: December 17, 2020 (version 3)

Copyright

© 2020, Wang et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,599
    views
  • 297
    downloads
  • 17
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Dennis Wang
  2. James Hensman
  3. Ginte Kutkaite
  4. Tzen S Toh
  5. Ana Claudia Paulo Galhoz
  6. Jonathan R Dry
  7. Julio Saez-Rodriguez
  8. Mathew J Garnett
  9. Michael P Menden
  10. Frank Dondelinger
(2020)
A statistical framework for assessing pharmacological response and biomarkers using uncertainty estimates
eLife 9:e60352.
https://doi.org/10.7554/eLife.60352

Share this article

https://doi.org/10.7554/eLife.60352

Further reading

    1. Computational and Systems Biology
    Antony M Jose
    Research Article

    Interacting molecules create regulatory architectures that can persist despite turnover of molecules. Although epigenetic changes occur within the context of such architectures, there is limited understanding of how they can influence the heritability of changes. Here, I develop criteria for the heritability of regulatory architectures and use quantitative simulations of interacting regulators parsed as entities, their sensors, and the sensed properties to analyze how architectures influence heritable epigenetic changes. Information contained in regulatory architectures grows rapidly with the number of interacting molecules and its transmission requires positive feedback loops. While these architectures can recover after many epigenetic perturbations, some resulting changes can become permanently heritable. Architectures that are otherwise unstable can become heritable through periodic interactions with external regulators, which suggests that mortal somatic lineages with cells that reproducibly interact with the immortal germ lineage could make a wider variety of architectures heritable. Differential inhibition of the positive feedback loops that transmit regulatory architectures across generations can explain the gene-specific differences in heritable RNA silencing observed in the nematode Caenorhabditis elegans. More broadly, these results provide a foundation for analyzing the inheritance of epigenetic changes within the context of the regulatory architectures implemented using diverse molecules in different living systems.

    1. Computational and Systems Biology
    2. Ecology
    Kazushi Tsutsui, Ryoya Tanaka ... Keisuke Fujii
    Research Article

    Collaborative hunting, in which predators play different and complementary roles to capture prey, has been traditionally believed to be an advanced hunting strategy requiring large brains that involve high-level cognition. However, recent findings that collaborative hunting has also been documented in smaller-brained vertebrates have placed this previous belief under strain. Here, using computational multi-agent simulations based on deep reinforcement learning, we demonstrate that decisions underlying collaborative hunts do not necessarily rely on sophisticated cognitive processes. We found that apparently elaborate coordination can be achieved through a relatively simple decision process of mapping between states and actions related to distance-dependent internal representations formed by prior experience. Furthermore, we confirmed that this decision rule of predators is robust against unknown prey controlled by humans. Our computational ecological results emphasize that collaborative hunting can emerge in various intra- and inter-specific interactions in nature, and provide insights into the evolution of sociality.